AURX (Nuo Therapeutics) Float Percentage Of Total Shares Outstanding: 48.41% (As of Jul. 06, 2026)


AURX Nuo Therapeutics Inc AURX
33 GF Score
Price $1.01
GF Value $4.26
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Nuo Therapeutics Float Percentage Of Total Shares Outstanding?

Nuo Therapeutics AURX 33 Float Percentage Of Total Shares Outstanding is 48.41% as of Jul. 06, 2026. GuruFocus rates AURX with a GF Score™ of 33/100 and a GF Value™ of $4.26 (Possible Value Trap). The stock has 4 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Nuo Therapeutics's float shares is 23.43 Mil. Nuo Therapeutics's total shares outstanding is 48.41 Mil. Nuo Therapeutics's float percentage of total shares outstanding is 48.41%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Nuo Therapeutics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Nuo Therapeutics's Institutional Ownership is 0.01%.

AURX
33GF Score
Nuo Therapeutics Inc AURX
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nuo Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Nuo Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=23.43/48.41
=48.41%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 48.41% mean?
Nuo Therapeutics (AURX) has a Float Percentage Of Total Shares Outstanding of 48.41% as of Jul. 06, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Nuo Therapeutics and its competitors.
Is Nuo Therapeutics' Float Percentage Of Total Shares Outstanding too high?
Nuo Therapeutics' current Float Percentage Of Total Shares Outstanding is 48.41%. Overall, Nuo Therapeutics has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nuo Therapeutics' Float Percentage Of Total Shares Outstanding compare to PDSB and LTRN?
Nuo Therapeutics' Float Percentage Of Total Shares Outstanding of 48.41% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Nuo Therapeutics and its competitors. Nuo Therapeutics's current Float Percentage Of Total Shares Outstanding is 48.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nuo Therapeutics (AURX) is currently considered Possible Value Trap. The stock's GF Value™ is $4.26, compared to a current price of $1.01 — trading 76.3% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 48.41%. Nuo Therapeutics' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Nuo Therapeutics (AURX), the current Float Percentage Of Total Shares Outstanding is 48.41% as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nuo Therapeutics (AURX) Overvalued in 2026?

Based on GuruFocus' analysis, Nuo Therapeutics stock appears to be undervalued. The current stock price of $1.01 is trading 76.3% below its estimated GF Value™ of $4.26. GuruFocus considers Nuo Therapeutics to be Possible Value Trap.

Key valuation signals for AURX:

  • Float Percentage Of Total Shares Outstanding: 48.41%
  • GF Value™: $4.26 vs. price of $1.01 (76.3% below fair value)
  • GF Score™: 33/100 with 4 warning signs

No single metric tells the full story. See the AURX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nuo Therapeutics Business Description

Address 8285 El Rio Street, Suite 190, Houston, TX, USA, 77054
Nuo Therapeutics Inc is a commercial-stage medical device company engaged in developing and marketing products for chronic wound care. The company operates as a single segment focused on regenerative therapies that utilize autologous (patient-derived) biological materials to promote natural healing. Its primary commercial product is the Aurix System, a point-of-care technology that produces platelet-rich plasma (PRP) therapy from a patient's own blood for use in the treatment of chronic wounds.
33GF Score

Get the complete analysis for AURX

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.01
Price
$4.26
GF Value